Advertisements


Mark Cuban Picks These 2 Cryptocurrencies For The Most Upside

One of the most vocal bulls of Dogecoin (CRYPTO: DOGE) in 2021 has been Mark Cuban. The Dallas Mavericks began accepting Dogecoin as a form of payment for tickets and merch earlier this year, but DOGE might not be Cuban’s favorite cryptocurrency anymore. read more.....»»

Category: blogSource: benzingaOct 13th, 2021

DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Beat Estimates

DENTSPLY SIRONA's (XRAY) third-quarter results benefit from strong segmental performance. DENTSPLY SIRONA Inc. XRAY reported third-quarter 2021 adjusted earnings per share (EPS) of 68 cents, beating the Zacks Consensus Estimate of 65 cents by 4.6%. The bottom line improved 1.5% on a year-over-year basis.GAAP EPS in the quarter was 47 cents, compared with the year-ago quarter’s figure of 25 cents.RevenuesFor the quarter, revenues amounted to $1.07 billion, surpassing the Zacks Consensus Estimate by 4%. The top line increased 19.4% year over year. Sales grew 21.1% on an organic basis.Business DetailsConsumablesConsumable revenues grew 12.4% year over year and 15.9% on an organic basis in the third quarter to $440 million. Per management, the upside was driven by increase in sales of all product categories in the quarter.DENTSPLY SIRONA Inc. Price, Consensus and EPS Surprise DENTSPLY SIRONA Inc. price-consensus-eps-surprise-chart | DENTSPLY SIRONA Inc. QuoteTechnologies & EquipmentTechnologies & Equipment revenues were up 24.8% year over year to $629 million in the reported quarter. On an organic basis, net sales rose 25.3%. Sales growth across all product categories led to the improvement.Revenues by GeographyIn the United States, revenues increased 25.3% to $399 million. Rest of World revenues climbed 20.1% year over year to $271 million. European revenues grew 13.6% year over year to $399 million.Margin AnalysisGross profit in the reported quarter amounted to $591 million, up 33.7% on a year-over-year basis. Gross margin was 55.3%, expanding 590 basis points (bps).Selling, general and administrative expenses were $394 million, up 25.1% from the year-ago quarter. Research and development expenses amounted to $35 million, up 29.6% from the prior-year quarter.Operating profit was $159 million, up 93.9% from the year-ago quarter. Operating margin was 14.9%, expanding 570 bps on a year-over-year basis.Financial ConditionDENTSPLY SIRONA exited the third quarter of 2021 with cash and cash equivalents of $281 million, down from $332 million in the second quarter of 2021.Cumulative net cash provided by operating activities at the end of the third quarter was $435 million compared with $372 million in the year-ago period.2021 GuidanceOn the basis of the third-quarter 2021 performance and the sustained gradual recovery in the global dental market, DENTSPLY SIRONA has updated its 2021 earnings outlook.The company projects 2021 revenues within $4.25-$4.30 billion (compared to the prior guided range of $4.10-$4.30 billion), up around 27-30% on a reported basis and 22-25% on an organic basis. The Zacks Consensus Estimate for the same is pegged at $4.28 billion.The company expects an adjusted EPS of $2.87-$2.92, (up from the previously guided range of $2.75-$2.90). The Zacks Consensus Estimate for the same stands at $2.88.Our TakeDENTSPLY SIRONA ended the third quarter on a strong note, wherein both earnings and revenues beat the consensus mark. The company saw revenue growth at both Consumables, and Technologies & Equipment segments in the quarter. It witnessed higher revenues in both domestic and international markets. Expansion in both gross and operating margins is another plus.Per management, the third-quarter performance highlights the sustained recovery in the dental market and solid demand for the company’s recent product launches.However, rise in selling, general and administrative expenses remains a concern.Zacks Rank and Key PicksCurrently, DENTSPLY SIRONA has a Zacks Rank #4 (Sell).Some better-ranked stocks in the broader medical space that have already announced their quarterly results are Thermo Fisher Scientific Inc. TMO, West Pharmaceutical Services, Inc. WST, and AngioDynamics, Inc. ANGO. While both Thermo Fisher and AngioDynamics sport a Zacks Rank of 1 (Strong Buy), West Pharmaceutical carries a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Thermo Fisher reported third-quarter 2021 adjusted EPS of $5.76, which beat the Zacks Consensus Estimate by 23.3%. Third-quarter revenues of $9.33 billion outpaced the consensus mark by 12%.West Pharmaceutical reported third-quarter 2021 adjusted EPS of $2.06, which surpassed the Zacks Consensus Estimate by 13.2%. Third-quarter revenues of $706.5 million outpaced the Zacks Consensus Estimate by 3.2%.AngioDynamics reported first-quarter fiscal 2022 loss per share of 2 cents, narrower than the Zacks Consensus Estimate of a loss of 5 cents. Revenues of $76.9 million surpassed the Zacks Consensus Estimate by 8.4%. Zacks' Top Picks to Cash in on Artificial Intelligence In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create "the world's first trillionaires." Zacks' urgent special report reveals 3 AI picks investors need to know about today.See 3 Artificial Intelligence Stocks With Extreme Upside Potential>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report DENTSPLY SIRONA Inc. (XRAY): Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksNov 4th, 2021

AmerisourceBergen (ABC) Q4 Earnings & Revenues Top Estimates

AmerisourceBergen's (ABC) fiscal fourth-quarter results benefit from segmental growth. AmerisourceBergen Corporation ABC reported fourth-quarter fiscal 2021 adjusted earnings per share (EPS) of $2.39, which surpassed the Zacks Consensus Estimate of $2.36 by 1.3%. The bottom line improved 26.5% year over year.The better-than-expected bottom-line performance can be attributed to higher adjusted operating income. However, increase in interest expense and higher diluted share count partially offset the improvement.GAAP EPS in the quarter under review was $2.08, against the year-ago quarter’s loss of $23.74.For fiscal 2021, the company reported adjusted EPS of $9.26, up 17.2% from the previous period. The metric outpaced the consensus mark by 0.2%.Revenue DetailsRevenues increased 19.6% to $58.91 billion in the reported quarter. The top line beat the Zacks Consensus Estimate by 3.9%.For fiscal 2021, the company reported revenues of $213.99 billion, up 12.7% from fiscal 2020. The top line beat the consensus mark by 1.4%.Segmental AnalysisPharmaceutical Distribution SegmentRevenues at this segment totaled $51.25 billion, reflecting an increase of 8.4% on a year-over-year basis on the back of increase in specialty product sales, including COVID-19 treatments coupled with overall market growth.Segmental operating income was $472.1 million, up 10.9% year over year. Solid performance across the company’s distribution businesses, which include higher sales of specialty products, contributed to the upside.AmerisourceBergen Corporation Price, Consensus and EPS Surprise AmerisourceBergen Corporation price-consensus-eps-surprise-chart | AmerisourceBergen Corporation QuoteOther SegmentThis segment includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI Veterinary Supply.Revenues at this segment were $7.70 billion, up 286.8% year over year. The upside was driven by growth across all three operating segments and the acquisition of Alliance Healthcare.Operating income in the segment was $223.3 million in the quarter, up 113.6% year over year primarily due to buyout of Alliance Healthcare.Margin AnalysisIn the quarter under review, AmerisourceBergen reported an adjusted gross profit of $2.01 billion, up 51.3% on a year-over-year basis. As a percentage of revenues, adjusted gross margin was 3.4% in the quarter, up 70 basis points (bps) a year-over-year basis.The company reported an adjusted operating income of $694.1 million, up 31% year over year. As a percentage of revenues, adjusted operating margin was 1.2% in the quarter, which expanded 10 bps from the year-ago quarter.Financial PositionThe company exited the quarter with cash and cash equivalents worth $2.55 billion remaining flat on a sequential basis.Cumulative net cash used in operating activities at the end of the fiscal fourth quarter totaled $2.67 billion compared with $2.21 billion in the prior-year quarter.Dividend UpdateIn November, AmerisourceBergen’s board of directors declared a quarterly dividend of 46 cents per share, which is higher than its quarterly dividend rate of 44 cents per share.Segment Realignment UpdateIt is worth mentioning that AmerisourceBergen made a strategic evaluation of its reporting structure in order to represent its expanded international presence because of the June 2021 buyout of Alliance Healthcare. Consequently, starting from the first quarter of fiscal 2022, the company has realigned its reporting structure under two reportable segments — U.S. Healthcare Solutions and International Healthcare Solutions.Fiscal 2022 GuidanceAmerisourceBergen issued its fiscal 2022 outlook, highlighting growth in both of its new reportable units.Adjusted EPS is now estimated to be $10.50-$10.80. The Zacks Consensus Estimate currently stands at $10.62.The company estimates revenue growth in the high-single-digit to low-double digit percent range.With respect to the U.S. Healthcare Solutions segment, revenues are expected in the band of $207 billion to $212 billion, representing growth of 2-5%. Revenues at International Healthcare solutions business is projected to be around $26 billion to $27 billion.Adjusted operating income is projected to grow in the mid-to high-teens percent range.Operating income at the U.S. Healthcare Solutions segment is anticipated between $2.33 billion and $2.4 billion, reflecting growth of 3-6%.For the International Healthcare solutions segment, the metric is estimated to grow in the range of $685 million to $715 million.Adjusted free cash flow is estimated to be around $2 billion to $2.5 billion.Summing UpAmerisourceBergen exited the fiscal fourth quarter on a strong note, wherein both earnings and revenues beat the consensus mark. The company continues to gain from its Pharmaceutical segment and World Courier business, which have been generating substantial profits for quite some time. Also, expansion in both gross and operating margins is a positive.Per management, during the fourth quarter, the company delivered robust growth in fiscal 2021 and undertook crucial steps to further boost its strategic positioning.However, the company faces other headwinds like conversion of branded drugs and lower price generics. Cut-throat competition in the MedTech space remains a concern.Zacks RankCurrently, AmerisourceBergen carries a Zacks Rank #3 (Hold).Earnings of Other MedTech Majors at a GlanceSome better-ranked stocks in the broader medical space that have already announced their quarterly results are Thermo Fisher Scientific Inc. TMO, West Pharmaceutical Services, Inc. WST, and AngioDynamics, Inc. ANGO. While both Thermo Fisher and AngioDynamics sport a Zacks Rank of 1 (Strong Buy), West Pharmaceutical carries a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Thermo Fisher reported third-quarter 2021 adjusted EPS of $5.76, which beat the Zacks Consensus Estimate by 23.3%. Third-quarter revenues of $9.33 billion outpaced the consensus mark by 12%.West Pharmaceutical reported third-quarter 2021 adjusted EPS of $2.06, which surpassed the Zacks Consensus Estimate by 13.2%. Third-quarter revenues of $706.5 million outpaced the Zacks Consensus Estimate by 3.2%.AngioDynamics reported first-quarter fiscal 2022 loss per share of 2 cents, narrower than the Zacks Consensus Estimate of a loss of 5 cents. Revenues of $76.9 million surpassed the Zacks Consensus Estimate by 8.4%. Zacks' Top Picks to Cash in on Artificial Intelligence In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create "the world's first trillionaires." Zacks' urgent special report reveals 3 AI picks investors need to know about today.See 3 Artificial Intelligence Stocks With Extreme Upside Potential>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report AmerisourceBergen Corporation (ABC): Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksNov 4th, 2021

Brinker (EAT) Earnings & Revenues Match Estimates in Q1

Brinker (EAT) first-quarter fiscal 2022 results benefit from increase in traffic and comps. Brinker International, Inc. EAT reported first-quarter fiscal 2022 results, wherein both earnings and revenues matched the Zacks Consensus Estimate. However, both the metrics improved year over year. The company benefited from robust performance of Chili's and Maggiano's.Earnings & Revenue DiscussionThe company’s adjusted earnings per share was 34 cents, in line with the Zacks Consensus Estimate. Brinker had reported an adjusted earnings of 28 cents in the year-ago quarter.Quarterly revenues of $876.4 million matched the consensus mark. The top line improved 18.4% on a year-over-year basis.Brinker International, Inc. Price, Consensus and EPS Surprise Brinker International, Inc. price-consensus-eps-surprise-chart | Brinker International, Inc. QuoteChili'sChili’s revenues in the fiscal first quarter jumped 14.7% year over year to $787.6 million, primarily owing to increase in dining room sales and traffic at the company’s franchise restaurants.Chili's company restaurant expenses (as a percentage of company sales) in the fiscal first quarter increased to 89.4% year over year from 87.5%. The increase was primarily due to rise in restaurant labor costs, which include wage rates, training and overtime. Higher repairs and maintenance expenses, and increase in utilities expenses also drove expenses. Traffic in the quarter under review climbed 9.4% year over year.In first-quarter fiscal 2022, company-owned comps advanced 17% year over year, against a decline of 10.9% in the year-ago quarter. The segment’s company-owned comps increased 13.4% in the fiscal first quarter, compared with the same period in 2021.Comps at Chili's franchised restaurants increased 23.1% against a decline of 11.5% in the year-ago quarter. At international franchised Chili’s restaurants, the same surged 32% versus the year-ago quarter’s decrease of 21.9%. Meanwhile, at the U.S. franchised units, comps climbed 17.8% against the year-ago quarter’s slump of 5.6%.At Chili's, domestic comps (including company-owned and franchised) climbed 13.8% year over year against the prior-year quarter’s decline of 7%.Maggiano'sMaggiano's sales surged 65.7% year over year to $88.8 million, primarily due to increase in dining and banquet room sales, and higher delivery sales. The upside, however, was offset by decrease in To-Go sales. Comps increased 62.6% year over year. Traffic in the quarter rose 39.1% year over year.Maggiano's company restaurant expenses (as a percentage of company sales) in the fiscal first quarter came in at 91.4%, compared with 100.2% in the prior-year quarter. The decrease was primarily due to sales leverage and lower To-Go supplies expenses. Nevertheless, the downside was negated by increased restaurant labor costs including training, wage rates, overtime and manager bonuses, higher repairs and maintenance expenses.Operating ResultsTotal operating costs and expenses contracted to $850.8 million from $715.7 million in the year-ago quarter. Restaurant operating margin — as a percentage of company sales — was 10.4% compared with 11.6% in the prior-year quarter.Balance SheetAs of Sep 29, 2021, cash and cash equivalents amounted to $31.2 million compared with $58.8 million as on Sep 23, 2020.Long-term debt was $999.7 million as of Sep 29 30, 2021, compared with $917.9 million on Jun 30, 2021. Total shareholders’ deficit in the reported quarter was ($325.5) million compared with ($303.3) million as of Jun 30, 2021.Fiscal 2022The company has reaffirmed its fiscal 2022 guidance, which was released on Aug 18. It continues to anticipate net revenues in the range of nearly $3.75 billion to $3.85 billion. Earnings per share are anticipated to be between $3.50 and $3.80.Zacks Rank & Key PicksBrinker carries a Zacks Rank #5 (Strong Sell). Some better-ranked stocks in the Zacks Retail - Restaurants industry space are McDonald's Corporation MCD, Noodles & Company NDLS and Dave & Buster's Entertainment, Inc. PLAY. Denny's sports a Zacks Rank #1 (Strong Buy), while Noodles & Company and Dave & Buster's carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.McDonald's has a three-five-year earnings per share growth rate of 11.9%.Noodles & Company’s 2021 earnings are expected to surge 182.8%.Dave & Buster's has a trailing four-quarter earnings surprise of 201.8%, on average. Zacks' Top Picks to Cash in on Artificial Intelligence In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create "the world's first trillionaires." Zacks' urgent special report reveals 3 AI picks investors need to know about today.See 3 Artificial Intelligence Stocks With Extreme Upside Potential>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report McDonald's Corporation (MCD): Free Stock Analysis Report Brinker International, Inc. (EAT): Free Stock Analysis Report Noodles & Company (NDLS): Free Stock Analysis Report Dave & Buster's Entertainment, Inc. (PLAY): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Category: topSource: zacksNov 4th, 2021

Lincoln National (LNC) Q3 Earnings Miss Estimates, Up Y/Y

Lincoln National's (LNC) third-quarter earnings miss estimates but improve significantly year over year driven by solid segmental contributions and lower expenses. Lincoln National Corporation LNC reported third-quarter 2021 adjusted earnings of $1.62 per share, which missed the Zacks Consensus Estimate by 36%. However, the bottom line compared favorably with the prior-year quarter’s loss of 72 cents per share.The company’s quarterly results benefited from growing sales, pricing discipline, cost-curbing efforts and share buybacks. The upside, however, was partly offset by decline in revenues and escalated COVID-linked claims.Adjusted operating revenues improved 8.7% year over year to $5.2 billion in the third quarter on account of solid contributions by all the four segments of the company — Annuities, Retirement Plan Services, Life Insurance and Group Protection. The top line beat the consensus mark by 6.7%.Total expenses of $4.9 billion declined 0.6% year over year primarily due to lower costs related to benefits.Lincoln National Corporation Price, Consensus and EPS Surprise Lincoln National Corporation price-consensus-eps-surprise-chart | Lincoln National Corporation QuoteSegmental PerformanceThe Annuities segment’s operating income soared 72% year over year to $338 million in the third quarter, courtesy of solid equity market performance paving the way for increased account values. Operating revenues advanced 12.5% year over year to $1.3 billion. Total annuity deposits increased 7% year over year to $2.7 billion driven by well-performing fixed annuities and variable annuities with guaranteed living benefits.The Retirement Plan Services segment reported operating income of $60 million, which climbed 20% year over year. The upside can be attributed to increased account values stemming from robust equity market performance, strong returns from the company’s alternative investment portfolio and consistent expense efficiency. Operating revenues of $328 million rose 5.5% year over year. Total deposits of $2.4 billion inched up 2% year over year in the quarter under review on the back of recurring deposits’ growth.Operating income in the Life Insurance segment amounted to $93 million, against the prior-year quarter’s loss from operations of $311 million. The substantial growth was supported by solid returns stemming from the company’s alternative investment portfolio. Operating revenues improved 9.3% year over year to $2.3 billion. Total Life Insurance sales, however, declined 10.8% year over year to $166 million in the third quarter.The Group Protection segment incurred a loss from operations of $32 million, versus the prior-year quarter’s income from operations of $6 million. Results were hurt by elevated mortality impacts stemming from the pandemic. Operating revenues of $1.2 billion grew 5% year over year. Total sales dipped 2% year over year to $48 million in the quarter under review.Financial Update (as of Sep 30, 2021)The company exited the third quarter with cash and invested cash of $2.6 billion, which inched up 0.7% year over year.Total assets of $377.1 billion increased 8.4% year over year.Long-term debt during the quarter amounted to $6.3 billion, down 5.8% year over year.Shareholders’ equity declined 1.8% year over year to $21.2 billion.Book value per share, excluding accumulated other comprehensive income (AOCI), increased 8.2% year over year to $76.96.Adjusted operating return on equity (ROE) excluding AOCI, came in at 8.6%, against the year-ago quarter’s negative figure of 3.9%.Share Repurchase UpdateThe company bought back shares worth $200 million in the third quarter. Via an accelerated share buyback program, the company recently started incremental repurchases linked with its block transaction.Dividend Hike AnnouncedConcurrently, the company’s board of directors approved a 7% increase in the quarterly dividend as well. The new dividend of 45 cents per share, compared to the prior payout of 42 cents, will be paid on Feb 1, 2022 to shareholders of record as on Jan 10, 2022.Zacks RankLincoln National presently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Performance of Other InsurersOf the insurance industry players that have reported third-quarter results so far, the bottom line of Athene Holding Ltd. ATH, MetLife, Inc. MET and Sun Life Financial Inc. SLF beat the Zacks Consensus Estimate. Zacks' Top Picks to Cash in on Artificial Intelligence In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create "the world's first trillionaires." Zacks' urgent special report reveals 3 AI picks investors need to know about today.See 3 Artificial Intelligence Stocks With Extreme Upside Potential>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Lincoln National Corporation (LNC): Free Stock Analysis Report MetLife, Inc. (MET): Free Stock Analysis Report Sun Life Financial Inc. (SLF): Free Stock Analysis Report Athene Holding Ltd. (ATH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksNov 4th, 2021

Here"s What to Expect Ahead of Citrix"s (CTXS) Q3 Earnings

Citrix's (CTXS) Q3 performance is likely to gain from the adoption of workspace solutions. Ongoing business transition to a subscription-based model is expected to have acted as a headwind. Citrix Systems CTXS is scheduled to release third-quarter 2021 results on Nov 4.For the to-be-reported quarter, the company expects revenues between $765 million and $775 million. The Zacks Consensus Estimate for revenues is pegged at $770.5 million, which indicates an increase of 0.4% from the year-ago quarter’s levels.Citrix expects non-GAAP earnings in the range of 85-90 cents per share. The consensus mark for earnings has been steady at 88 cents per share in the past 30 days. The estimate suggests a decline of 36.2% compared with the prior-year quarter’s reported figure.The company beat the Zacks Consensus Estimate for earnings in each of the trailing four quarters, the average surprise being 6.8%.Citrix Systems, Inc. Price and EPS Surprise  Citrix Systems, Inc. price-eps-surprise | Citrix Systems, Inc. Quote Factors Likely to Have Influenced Q3 PerformanceCitrix’s third-quarter performance is anticipated to have benefited from the healthy adoption of its digital workspace and desktop virtualization solutions, amid the continuation of remote work trends and hybrid work innovation.Citrix’s efforts to enhance the security capabilities of its offerings amid the increasing threat of cyber-attacks is likely to have driven the incremental adoption of its products. This is expected to have acted as a tailwind.In September 2021, Citrix rolled out a cloud-powered solution — Citrix App Delivery and Security Service — designed primarily to simplify and automate the process of app delivery like provisioning, on-boarding and management. This will help IT teams to provide augmented user experience.In the third quarter, companies including Hollands Kroon, Peninsula Health, Kaizen, Australia-based CoreSenses, University of Toronto Mississauga, Synopsys SNPS and Southern Housing Group selected Citrix’s digital workspace solutions.Acquisition (February 2021) of Wrike is expected to have boosted the top-line performance. Wrike provides SaaS-based collaborative work management solutions for enterprises.The Zacks Consensus Estimate for the third-quarter Subscription revenues is pegged at $361 million, which indicates a year-over-year improvement of 37.3%. The consensus estimate for Support and services revenues is pegged at $361 million, which indicates a year-over-year decline of 13.4%.However, Citrix’s performance is likely to have been affected by the ongoing business transition to a subscription-based model. The transition is exerting pressure on Product and License revenues as well as Support and Services revenues.In the last reported quarter, the company announced that it was implementing several changes to its sales organization as well as processes and go-to-market strategies in the second half of 2021 to boost its SaaS business.Increasing investments on portfolio expansion via product enhancements and acquisitions — amid stiff competition from VMware's Horizon, Workspace ONE, and AirWatch offerings and Amazon’s WorkSpaces — are anticipated to have put pressure on margins in the third quarter.What the Zacks Model UnveilsOur proven model does not conclusively predict an earnings beat for Citrix this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat.Citrix has an Earnings ESP of 0.00% and a Zacks Rank #3, at present, making earnings beat prediction difficult. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Stocks to ConsiderHere are some stocks, which you may consider, as our proven model shows that these have the right mix of elements to beat estimates this time around:HP Inc HPQ has an Earnings ESP of +1.89% and a Zacks Rank #2, presently. You can see the complete list of today's Zacks #1 Rank stocks here.Synaptics Incorporated SYNA has an Earnings ESP of +0.38% and a Zacks Rank #2. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. You know this company from its past glory days, but few would expect that it's poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks' Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report HP Inc. (HPQ): Free Stock Analysis Report Citrix Systems, Inc. (CTXS): Free Stock Analysis Report Synopsys, Inc. (SNPS): Free Stock Analysis Report Synaptics Incorporated (SYNA): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksNov 3rd, 2021

Freshpet (FRPT) to Post Q3 Earnings: What Awaits the Stock?

Freshpet's (FRPT) third-quarter performance is likely to have gained from strong consumption trends. However, rising labor and beef costs are likely to be a drag. Freshpet, Inc. FRPT — a renowned pet food products company — is likely to register top-line growth when it reports third-quarter 2021 results on Nov 8, after market close. The Zacks Consensus Estimate for revenues is pegged at $115.7 million, which indicates growth of 37.4% from the prior-year quarter’s reported figure.The Zacks Consensus Estimate for the third-quarter bottom line is currently pegged at 9 cents per share, which suggests no changes from the year-ago quarter’s earnings. The consensus mark has remained stable in the past 30 days. The company incurred a loss in the past three quarters. It has a trailing four-quarter negative earnings surprise of 399.4%, on average.Key Aspects to NoteFreshpet’s top line during the third quarter is likely to have gained from the company’s strong product offerings. To boost portfolio strength, the company has been engaged in well-chalked innovations. It has been striving to expand fresh and natural ingredients-based pet food products. The company is also likely to have gained from improved distribution and retail availability, backed by enhanced production levels.Freshpet’s pet specialty channel is likely to have performed well during the quarter in review, driven by expanded consumption. It is also likely to have gained from expanded Freshpet fridges across stores. The company’s sturdy e-commerce platform and efforts to boost international business are likely to have been an upside.However, the company’s performance in the third quarter is likely to have been adversely impacted by industry-wide inflationary trends, especially in labor and logistics costs. Higher beef costs and production expenses are also expected to have been a drag.Freshpet, Inc. Price, Consensus and EPS Surprise  Freshpet, Inc. price-consensus-eps-surprise-chart | Freshpet, Inc. Quote What the Zacks Model UnveilsOur proven model does not conclusively predict an earnings beat for Freshpet this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Freshpet has a Zacks Rank #3 and an Earnings ESP of 0.00%.Stocks With Favorable CombinationHere are some companies you may want to consider as our model shows that they have the right combination of elements to post an earnings beat:United Natural Foods UNFI currently has an Earnings ESP of +9.24% and a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.Tyson Foods TSN currently has an Earnings ESP of +2.51% and is Zacks #2 Ranked.Coty COTY currently has an Earnings ESP of +50.00% and a Zacks Rank of 3. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. You know this company from its past glory days, but few would expect that it's poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks' Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tyson Foods, Inc. (TSN): Free Stock Analysis Report Freshpet, Inc. (FRPT): Free Stock Analysis Report United Natural Foods, Inc. (UNFI): Free Stock Analysis Report Coty (COTY): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksNov 3rd, 2021

Marriott (MAR) Q3 Earnings Beat Estimates, Increase Y/Y

Marriott's (MAR) third-quarter 2021 performance benefits from solid leisure demand as well as the opening of many key international borders. Marriott International, Inc. MAR reported solid third-quarter 2021 results, with earnings and revenues beating the Zacks Consensus Estimate as well as increasing on a year-over-year basis.During the quarter, the company witnessed solid demand in Europe owing to the opening of key international borders. It reported sequential improvements in revenue per available room (RevPAR), occupancy and average daily rate (ADR) on account of solid leisure demand. Although the Delta variant had negatively impacted business transient demand (during the second half of the quarter), demand is stated to have picked up in October. With global trends improving, the company expects the recovery momentum to continue in the upcoming periods as well.Earnings & Revenues DiscussionMarriott International, Inc. Price, Consensus and EPS Surprise  Marriott International, Inc. price-consensus-eps-surprise-chart | Marriott International, Inc. Quote In the quarter under review, Marriott’s adjusted earnings per share were 99 cents, which surpassed the Zacks Consensus Estimate of 97 cents. In the prior-year quarter, the company had reported adjusted earnings of 13 cents per share.Quarterly revenues of $3,946 million surpassed the consensus mark of $3,468 million. Moreover, the top line surged 75% on a year-over-year basis. During the quarter, revenues from Base management and Franchise fee came in at $190 million and $533 million compared with $87 million and $279 million reported in the prior-year quarter.RevPAR & MarginsIn the quarter under review, RevPAR for worldwide comparable system-wide properties fell 25.8% (in constant dollars) compared with 2019 levels. The decline was primarily driven by a fall in occupancy and ADR. Occupancy and ADR declined 16.8% and 4.4%, respectively, from 2019 levels. These metrics were impacted by the coronavirus pandemic.Comparable system-wide RevPAR in Asia Pacific (excluding China) fell 63.9% (in constant dollars) from 2019 levels. Notably, occupancy and ADR had fallen 37.9% and 26%, respectively, from 2019 levels. Comparable system-wide RevPAR in Greater China fell 27.4% from 2019 levels.On a constant-dollar basis, international comparable system-wide RevPAR fell 40.7% compared with 2019 levels. Occupancy and ADR dropped 25.4% and 7.9%, respectively, from 2019 levels. Comparable system-wide RevPAR in Europe as well as Caribbean & Latin America declined 43.5% and 17.8%, respectively, from 2019 levels.Total expenses during the quarter increased 69.9% year over year to $3,401 million, primarily owing to a rise in Reimbursed expenses.During the third quarter, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) amounted to $683 million compared with $327 million in the prior-year quarter.Balance sheetAt the end of the third quarter, Marriott's total debt amounted to $9 billion compared with $9.5 billion in the previous quarter.Unit DevelopmentsAt the end of third-quarter 2021, Marriott's development pipeline totaled nearly 2,769 hotels, with approximately 477,000 rooms. Nearly 206,000 rooms were under construction.During the quarter, the company added 114 new properties (17,456 rooms) to its worldwide lodging portfolio.Zacks Rank & Key PicksMarriott currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Some better-ranked stocks in the Zacks Consumer Discretionary sector include Golden Entertainment, Inc. GDEN, Wyndham Hotels & Resorts, Inc. WH and Choice Hotels International, Inc. CHH. Golden Entertainment sports a Zacks Rank #1, while Wyndham Hotels and Choice Hotels carry a Zacks Rank #2 (Buy).Golden Entertainment’s 2021 earnings are expected to surge 232.1%.Wyndham Hotels has a trailing four-quarter earnings surprise of 61.9%, on average.Choice Hotels has three-five-year earnings per share growth rate of 35.2%. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. You know this company from its past glory days, but few would expect that it's poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks' Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Marriott International, Inc. (MAR): Free Stock Analysis Report Choice Hotels International, Inc. (CHH): Free Stock Analysis Report Golden Entertainment, Inc. (GDEN): Free Stock Analysis Report Wyndham Hotels & Resorts (WH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksNov 3rd, 2021

Trane Technologies (TT) Q3 Earnings Miss Estimates, Up Y/Y

Trane Technologies' (TT) third-quarter 2021 earnings and revenues improve year over year. Trane Technologies plc TT reported lower-than-expected third-quarter 2021 results.Adjusted EPS of $1.8 misses the Zacks Consensus Estimate by 3.2% but increased 5% year over year. Revenues of $3.7 billion lagged the consensus mark by 2% but increased 6% year over year on a reported basis and 4% organically. Bookings were up 22% year over year on a reported basis and 20% organically, to $4.3 billion.The company’s shares have gained 33.4% over the past year against 10.9% decline of the industry it belongs to.Trane Technologies plc Price and EPS Surprise Trane Technologies plc price-eps-surprise | Trane Technologies plc QuoteRevenues and Bookings Up in all SegmentsThe Americas segment’s revenues of $2.9 billion increased 6% year over year on a reported basis and 4% on an organic basis. Bookings increased 22% on a reported basis and 20% organically, to $3.3 billion.Europe, Middle East and Africa (EMEA) segment’s revenues came in at $495 million, up 11% year over year on a reported basis and 8% organically. Bookings were up 29% on a reported basis and 25% organically, to $574.4 million.Revenues from the Asia Pacific segment were up 3% year over year on a reported basis and 1% on an organic basis, to $314.5 million. Bookings of $372.1 million increased 14% on a reported basis and 11% organically.Strong Margin PerformanceAdjusted EBITDA came in at $670 million, up 2% year over year. Adjusted EBITDA margin declined 70 basis points (bps) to 18%. Adjusted operating income of $598 million increased 2% year over year with adjusted operating margin declining 60 bps to 16.1%.Key Balance Sheet and Cash Flow FiguresTrane ended the quarter with cash balance of $2.7 billion compared with $2.9 billion at the end of the previous quarter. Debt balance was $4.8 billion compared with $5 billion in the previous quarter.The company generated $1.2 billion of cash from operating activities while capital expenditures were $81 million. Free cash flow was $1.1 billion.2021 GuidanceTrane expects revenues to increase 13.5% on a reported basis and 11% on an organic basis. Adjusted EPS is expected to be $6.05, up 36% year over year but below the current Zacks Consensus Estimate of $6.07.Trane currently carries a Zacks Rank #4 (Sell).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Performance of Some Other Business Services CompaniesEquifax EFX reported better-than-expected third-quarter 2021 results. Adjusted earnings of $1.85 per share beat the Zacks Consensus Estimate by 7.6% but declined 1.1% on a year-over-year basis. Revenues of $1.22 billion outpaced the consensus estimate by 3.6% and improved 14.5% year over year.IQVIA Holdings IQV reported impressive third-quarter 2021 results, with earnings per share of $2.17 beating the consensus mark by 1.9% and improving 33.1% on a year-over-year basis. Total revenues of $3.39 billion outpaced the consensus estimate by 1% and increased 21.7% year over year.Omnicom OMC reported third-quarter 2021 adjusted earnings of $1.65 per share that beat the consensus mark by 20.4% and increased 36.4% year over year. Total revenues of $3.4 billionsurpassed the consensus estimate by 0.6% and increased 7.1% year over year. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. You know this company from its past glory days, but few would expect that it's poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks' Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Omnicom Group Inc. (OMC): Free Stock Analysis Report Equifax, Inc. (EFX): Free Stock Analysis Report Trane Technologies plc (TT): Free Stock Analysis Report IQVIA Holdings Inc. (IQV): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Category: topSource: zacksNov 3rd, 2021

H&R Block (HRB) Reports Narrower-Than-Expected Loss in Q1

H&R Block's (HRB) first-quarter fiscal 2022 revenues beat the Zacks Consensus Estimate. H&R Block, Inc. HRB reported first-quarter fiscal 2022 loss (excluding 7 cents from non-recurring items) of 78 cents per share, narrower than the Zacks Consensus Estimate of a loss of $1.05. Operating revenues of $192.6 million surpassed the Zacks Consensus Estimate by 14.8%.  Shares of H&R Block have gained 32.1% in the past year against a 5.8% decline of the industry.Image Source: Zacks Investment ResearchQuarterly Numbers in DetailU.S. assisted tax preparation, U.S. royalties, U.S. DIY tax preparation and international revenues came in at $33.6 million, $7.4 million, $4.1 million and $58.3 million, respectively.Emerald Card, Peace of Mind Extended Service Plan and Wave revenues were $28.3 million, $24.8 million and $19.1 million, respectively.Pretax loss came in at $197.3 million compared with a loss of $32.9 million in the year-ago quarter. Total operating expenses were $367 million, down 12% year over year (driven by lower tax pro compensation on lighter return volumes as the quarter took place after the 2021 filing deadline).H&R Block exited the quarter with cash and cash equivalents of $891.7 million compared with $934.3 million at the end of the prior quarter. Long-term debt was $1.98 billion compared with $1.5 billion (long-term debt and line of credit borrowings) at the end of the previous quarter.H&R Block used $3.1 billion of cash from operating activities and capex was $15.6 million. The company repurchased $166 million of shares and paid out dividends worth $48.9 million in the quarter.H&R Block, Inc. Price, Consensus and EPS Surprise  H&R Block, Inc. price-consensus-eps-surprise-chart | H&R Block, Inc. Quote H&R Block currently carries a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.Performance of Some Other Business Services CompaniesEquifax’s EFX third-quarter 2021 adjusted earnings of $1.85 per share beat the Zacks Consensus Estimate by 7.6%. The bottom line declined on a year-over-year basis. Revenues of $1.22 billion outpaced the consensus estimate by 3.6%. The top line increased 14.5% year over year on a reported basis and 14% on a local-currency basis.IQVIA’s IQV third-quarter 2021 adjusted earnings per share of $2.17 beat the consensus mark by 1.9% and rose 33.1% on a year-over-year basis. Total revenues of $3.39 billion outpaced the consensus estimate by 1%. The top line increased 21.7% year over year on a reported basis and 21.1% on a constant-currency basis.Omnicom’s OMC third-quarter 2021 adjusted earnings of $1.65 per share beat the consensus mark by 20.4% and increased 36.4% year over year. Total revenues of $3.4 billion surpassed the consensus estimate by 0.6% and increased 7.1% year over year.  Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. You know this company from its past glory days, but few would expect that it's poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks' Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Omnicom Group Inc. (OMC): Free Stock Analysis Report Equifax, Inc. (EFX): Free Stock Analysis Report H&R Block, Inc. (HRB): Free Stock Analysis Report IQVIA Holdings Inc. (IQV): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksNov 3rd, 2021

The Trade Desk (TTD) to Report Q3 Earnings: What"s in Store?

The Trade Desk's (TTD) third-quarter results are likely to benefit from strength in connected-TV ad spending, programmatic ad buying and a growing partner ecosystem. The Trade Desk TTD is set to release third-quarter 2021 results on Nov 8.For the quarter, the company expects revenues of at least $282 million.The Zacks Consensus Estimate for the top line is currently pegged at $283.6 million, indicating 31.2% growth from the year-ago quarter’s reported figure.The consensus mark for earnings has been unchanged at 16 cents per share over the past 30 days, suggesting 23.1% growth from the figure reported in the year-ago quarter. The Trade Desk Price and EPS Surprise The Trade Desk price-eps-surprise | The Trade Desk Quote The company’s earnings beat the Zacks Consensus Estimate in all the trailing four quarters, delivering an earnings surprise of 91.2%, on average.Let’s see how things have shaped up prior to this announcement:Factors to ConsiderThe Trade Desk’s top line, in the third quarter, is expected to have benefited from momentum in programmatic ad buying. The emergence of digital content boosted usage of the company’s inventory across all forms of Connected-TV (“CTV”). Strong CTV spending is expected to have continued in the to-be-reported quarter.At the end of the second quarter, The Trade Desk had roughly 10,000 CTV advertisers on its platform, up more than 50% year over year.The company is expected to have benefited from the launch of new version of its platform, Solimar.Consistent customer retention is expected to have perked up the company’s revenues during the quarter. The Trade Desk’s customer-retention rate has remained more than 95%, as it has for the previous seven years.However, accelerated spending is expected to have hurt bottom-line growth in the to-be-reported quarter.What Our Model IndicatesPer the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here.The Trade Desk has an Earnings ESP of 0.00% and a Zacks Rank #3. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Stocks to ConsiderHere are some companies worth considering, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle:Applied Materials AMAT has an Earnings ESP of +0.52% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.Synaptics SYNA has an Earnings ESP of +0.38% and a Zacks Rank #2.Blink Charging BLNK has an Earnings ESP of +8.33% and a Zacks Rank #3. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. You know this company from its past glory days, but few would expect that it's poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks' Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Applied Materials, Inc. (AMAT): Free Stock Analysis Report Synaptics Incorporated (SYNA): Free Stock Analysis Report The Trade Desk (TTD): Free Stock Analysis Report Blink Charging Co. (BLNK): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Category: topSource: zacksNov 3rd, 2021

Broadridge"s (BR) Q1 Earnings Surpass Estimates, Up Y/Y

Broadridge's (BR) first-quarter fiscal 2022 earnings and revenues increase year over year. Broadridge Financial Solutions, Inc. BR reported impressive first-quarter fiscal 2022 results, wherein both earnings and revenues beat the Zacks Consensus Estimate.Adjusted earnings of $1.07 per share beat the consensus estimate by 4.9% and were up 9% year over year. Total revenues of $1.2 billion surpassed the consensus mark by 4.6% and were up 17% year over year. The company generated closed sales of $30 million in the quarter, down 6% year over year.Shares of the company have gained 23.5% over the past year, underperforming the 37% growth of the industry it belongs to.Broadridge Financial Solutions, Inc. Price, Consensus and EPS Surprise Broadridge Financial Solutions, Inc. price-consensus-eps-surprise-chart | Broadridge Financial Solutions, Inc. QuoteLet’s check out the numbers in detail.Revenues by SegmentRevenues in the Investor Communication Solutions segment increased 14% from the year-ago quarter’s level to $854 million. Global Technology and Operations segment revenues came in at $341 million, up 21% from the year-ago quarter’s figure. The improvement was mainly driven by the Itiviti acquisition.Revenues by TypeRecurring fee revenues of $751 million increased 16% from the year-ago quarter’s level. Event-driven fee revenues came in at $76 million, up 69% year over year. Distribution revenues increased 11% year over year to $367 million.Operating ResultsAdjusted operating income of $177 million increased 17% year over year. Adjusted operating income margin stayed flat year over year at 14.8%.Balance Sheet and Cash FlowBroadridge exited the quarter with cash and cash equivalents of $317 million compared with $275 million at the end of the prior quarter. Long-term debt was $4.2 billion compared with $3.9 billion at the end of the prior quarter.The company used $135.4 million of cash in operating activities and capex was $5.7 million in the quarter. Broadridge paid out $66.8 million in dividends in the reported quarter.Fiscal GuidanceBroadridge expects recurring revenue growth of 12-15%. Adjusted earnings per share (EPS) growth is expected to be 11-15%. Adjusted operating income margin is estimated to be up by around 19%. Closed sales are anticipated between $240 million and $280 million.Broadridge currently carries a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Performance of Some Other Business Services CompaniesEquifax EFX reported better-than-expected third-quarter 2021 results. Adjusted earnings of $1.85 per share beat the Zacks Consensus Estimate by 7.6% but declined 1.1% on a year-over-year basis. Revenues of $1.22 billion outpaced the consensus estimate by 3.6% and improved 14.5% year over year.IQVIA Holdings IQV reported impressive third-quarter 2021 results, with earnings per share of $2.17 beating the consensus mark by 1.9% and improving 33.1% on a year-over-year basis. Total revenues of $3.39 billion outpaced the consensus estimate by 1% and increased 21.7% year over year.Omnicom OMC reported third-quarter 2021 adjusted earnings of $1.65 per share that beat the consensus mark by 20.4% and increased 36.4% year over year. Total revenues of $3.4 billion surpassed the consensus estimate by 0.6% and increased 7.1% year over year. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. You know this company from its past glory days, but few would expect that it's poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks' Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Broadridge Financial Solutions, Inc. (BR): Free Stock Analysis Report Omnicom Group Inc. (OMC): Free Stock Analysis Report Equifax, Inc. (EFX): Free Stock Analysis Report IQVIA Holdings Inc. (IQV): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksNov 3rd, 2021

Insperity (NSP) Beats on Q3 Earnings & Revenues, Tweaks View

Insperity's (NSP) third-quarter 2021 earnings decrease year over year while revenues improve. Insperity, Inc.NSP reported better-than-expected third-quarter 2021 results.Adjusted earnings of 89 cents per share beat the Zacks Consensus Estimate by 6% but decreased 2.2% year over year. The reported figure lies within the guidance of 74-93 cents.Revenues of $1.21 billion surpassed the consensus mark by 3.5% and increased 20% year over year. The upside was backed by 8% increase in revenues per worksite employees (WSEEs) and 11% increase in paid worksite employees.The average number of worksite employees paid per month, 257,560, inched up 11.1% year over year.So far this year, shares of Insperity have gained 51.4% compared with 49.8% rise of the industry it belongs to.Image Source: Zacks Investment ResearchOperating Results       Gross profit of $198.5 million increased 7.3% from the year-ago quarter. Gross margin of 16.4% declined from 18.4% in the year-ago quarter. Gross profit per worksite employee per month decreased 3.4% year over year to $257.Adjusted EBITDA increased 4.5% year over year to $60.1 million. Adjusted EBITDA per worksite employee per month decreased 6% to $78.Operating expenses increased 1.7% year over year to $158.9 million. Operating expenses per worksite employee per month decreased 8.4% to $206.Operating income increased 37.6% year over year to $39.6 million. Operating income per worksite employee per month grew 24.4% to $51.Insperity, Inc. Price, Consensus and EPS Surprise Insperity, Inc. price-consensus-eps-surprise-chart | Insperity, Inc. QuoteBalance Sheet & Cash FlowInsperity exited third-quarter 2021 with adjusted cash, cash equivalents and marketable securities of $227.57 million compared with $212.84 million at the end of the prior quarter. Long-term debt amounted to $369.40 million, flat sequentially.During the reported quarter, the company repurchased shares worth $11.3 million and paid out $17.4 million in cash dividends. Capital expenditures totaled $2.9 million.Q4 GuidanceFor fourth-quarter 2021, Insperity projects adjusted earnings in the range of 61-81 cents per share. The current Zacks Consensus Estimate of 76 cents lies within the guided range.Adjusted EBITDA is anticipated between $45 million and $56 million. Average WSEEs are expected in the range of 265,500-268,000.2021 GuidanceInsperity has updated its guidance for 2021. The company now projects adjusted earnings in the band of $4.25-$4.46 per share compared with the prior guidance of $4.00-$4.59. The current Zacks Consensus Estimate of $4.33 lies within the updated guidance.Adjusted EBITDA is now anticipated in the range of $271-$282 million compared with the prior guidance of $258-$288 million. Average WSEEs are expected in the range of 250,100-250,600 compared with the prior guidance of 247,100-249,500.Currently, Insperity carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Performance of Other Business Services CompaniesEquifax’s EFX third-quarter 2021 adjusted earnings of $1.85 per share beat the Zacks Consensus Estimate by 7.6% but declined on a year-over-year basis. Revenues of $1.22 billion outpaced the consensus estimate by 3.6% and improved 14.5% year over year on a reported basis and 14% on a local-currency basis.IQVIA’s IQV third-quarter 2021 adjusted earnings per share of $2.17 beat the consensus mark by 1.9% and improved 33.1% on a year-over-year basis. Total revenues of $3.39 billion outpaced the consensus estimate by 1% and increased 21.7% year over year on a reported basis and 21.1% on a constant-currency basis.Omnicom’s OMC third-quarter 2021 adjusted earnings of $1.65 per share beat the consensus mark by 20.4% and increased 36.4% year over year. Total revenues of $3.4 billion surpassed the consensus estimate by 0.6% and increased 7.1% year over year. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. You know this company from its past glory days, but few would expect that it's poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks' Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Omnicom Group Inc. (OMC): Free Stock Analysis Report Equifax, Inc. (EFX): Free Stock Analysis Report Insperity, Inc. (NSP): Free Stock Analysis Report IQVIA Holdings Inc. (IQV): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksNov 3rd, 2021

Charles River (CRL) Q3 Earnings Beat Estimates, EPS View Up

Charles River (CRL) exited the third quarter of 2021 with better-than-expected earnings on strength in the RMS, DSA and Manufacturing Solutions arms driving the top line. Charles River Laboratories International, Inc. CRL announced adjusted earnings per share (EPS) of $2.70 for third-quarter 2021, reflecting a 15.9% jump from the year-ago earnings of $2.33. The metric surpassed the Zacks Consensus Estimate by 5.1%.On a GAAP basis, earnings declined 0.9% year over year to $2.01.RevenuesRevenues in the third quarter totaled $895.9 million, missing the Zacks Consensus Estimate by 1.4%. Moreover, the top line improved 20.5% from the year-ago number (up 13.6% organically, excluding the impact of acquisition and foreign currency translation).Compared to the severe pandemic-hit third quarter of last year, Charles River’s third-quarter 2021 revenue growth was 1.8% (up 1.7% organically).Segment in DetailCharles River’s third-quarter total Research Models and Services (RMS) revenues of $171.3 million reflects an increase of 12.7% year over year (up 10.7% organically). Organic revenue growth was driven by the robust demand for research models, particularly in China, as well as higher revenues from research model services, particularly the Genetically Engineered Models and Services (GEMS) business. The pandemic-led favorable year-over-year comparison contributed 2.2% on a reported basis and 2.1% on an organic basis to RMS’ revenue growth in the third quarter.Charles River Laboratories International, Inc. Price, Consensus and EPS Surprise Charles River Laboratories International, Inc. price-consensus-eps-surprise-chart | Charles River Laboratories International, Inc. QuoteDiscovery and Safety Assessment (DSA) revenues of $531.8 million rose 15.3% (up 13% organically). Organic revenue growth was mainly driven by the robust demand from global biopharmaceutical and biotechnology clients in both Discovery Services and Safety Assessment businesses.Manufacturing Solutions revenues totaled $192.9 million, up 48.1% year over year (up 19.1% organically). Organic revenue growth was fueled by strong demand in the Biologics Testing Solutions and Microbial Solutions businesses.MarginsThe gross profit in the reported quarter was $337.2 million, up 16.6% from the prior-year quarter. The gross margin of 37.6% contracted 128 basis points (bps).Meanwhile, the selling, general & administrative expenses flared up 15.8% to $148.6 million.The adjusted operating income totaled $188.7 million, reflecting a 17.2% jump from the prior-year quarter. Further, the adjusted operating margin in the third quarter contracted 60 bps to 21.1%.Liquidity and Cash PositionCharles River exited the third quarter of 2021 with cash and cash equivalents of $212.5 million compared with $222.9 million at the end of second-quarter 2021.Cumulative net cash provided by operating activities at the end of the third quarter was $531.5 million compared with the prior year’s $408.2 million.Guidance UpdatedThe company updated its 2021 guidance, taking into account the impact of foreign exchange and the divestitures.For 2021, Charles River lowered its revenue guidance. Revenues are now expected to grow in the band of 19.5-20.5% compared with the earlier guidance of 20.5-22.5%. Organic revenue growth is now expected in the range of 13.5-14.5% versus the 13-15% projected earlier. The Zacks Consensus Estimate for total revenues is pegged at $3.56 billion, indicating a 21.8% rise from 2020.The adjusted EPS for 2021 are expected in the range of $10.20-$10.30, suggesting a rise from the earlier range of $10.10-10.35. The current Zacks Consensus Estimate is pegged at $10.26.Our TakeThe company exited the third quarter of 2021 with better-than-expected earnings. Results highlight 13.6% organic revenue growth, driven by strength across all three segments. Robust demand in the Biologics Testing Solutions and Microbial Solutions businesses drove Manufacturing Solutions in the reported quarter. The acquisitions of Cognate BioServices (Cognate) and Vigene Biosciences (Vigene) too contributed to growth in the Manufacturing Solutions arm. Strong customer uptake in the Discovery Services and Safety Assessment businesses instills optimism as well. Increased adjusted earnings guidance for the full year is an upside too.On the flip side, a lowered full-year revenue guidance raises concern. Rising operating costs and contraction in both margins does not bode well either. Stiff competition and foreign-currency fluctuation are other woes.Zacks Rank and Key PicksCharles River currently carries a Zacks Rank #4 (Sell).Some better-ranked stocks in the broader medical space that have announced quarterly results are Thermo Fisher Scientific Inc. TMO, SARTORIUS SARTF and West Pharmaceutical Services, Inc. WST.Thermo Fisher, flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2021 adjusted EPS of $5.76, which beat the Zacks Consensus Estimate by 23.3%. Revenues of $9.33 billion outpaced the consensus mark by 12%. You can see the complete list of today’s Zacks #1 Rank stocks here.SARTORIUS reported third-quarter 2021 adjusted EPS of $2.55, surpassing the Zacks Consensus Estimate by 7.6%. Revenues of $1.06 billion surpassed the Zacks Consensus Estimate by 5.2%. It currently carries a Zacks Rank #2 (Buy).West Pharmaceutical delivered third-quarter 2021 adjusted EPS of $2.06, which surpassed the Zacks Consensus Estimate by 13.2%. Revenues of $706.5 million outpaced the Zacks Consensus Estimate by 3.2%. It currently carries a Zacks Rank #2. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. You know this company from its past glory days, but few would expect that it's poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks' Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report Charles River Laboratories International, Inc. (CRL): Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report SARTORIUS (SARTF): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksNov 3rd, 2021

How Gildan Activewear (GIL) is Placed Ahead of Q3 Earnings

Gildan Activewear's (GIL) third-quarter 2021 results might show gains from the improving market trends, solid execution of its strategies and brand strength. We expect Gildan Activewear Inc. GIL to witness both the top and the bottom-line growth when it reports third-quarter 2021 earnings on Nov 4, before market open. The Zacks Consensus Estimate for quarterly earnings is pegged at 56 cents, which suggests a sharp rise from 30 cents earned in the year-earlier quarter. The consensus mark has increased a couple of cents in the past 30 days.The Zacks Consensus Estimate for third-quarter sales currently stands at $712 million, indicating an 18% increase from the prior-year quarter’s reported figure.A glance at the company’s performance in the last four quarters reflects that it delivered an earnings surprise of 133.2%, on average.Key Factors to NoteGildan Activewear’s quarterly performance might have benefited from improving market trends and recovery from the pandemic-led disruptions. Solid execution of its strategies including elimination of redundancy and complexity from the business, enhancement of business operations and cost-saving measures are likely to have contributed to the company’s performance.The company’s Back-to-Basics strategy bodes well. It mainly focuses on simplifying business and optimizing operations as well as streamlining administrative, marketing and merchandising activities. It has been gaining from strength in brands for a while. The company is also reinforcing its presence in the international markets. All the aforesaid factors are likely to have boosted Gildan Activewear’s performance in the to-be-reported quarter.On the flip side, supply-chain bottlenecks remain an industry-wide concern. Also, the company continues to endure tightness in raw material inputs and transportation-related issues, inducing inflationary pressures.What the Zacks Model UnveilsOur proven model predicts an earnings beat for Gildan Activewear this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Gildan Activewear, Inc. Price and EPS Surprise Gildan Activewear, Inc. price-eps-surprise | Gildan Activewear, Inc. QuoteGildan Activewear currently has a Zacks Rank #2 and an Earnings ESP of +7.14%.More Stocks With Favorable CombinationHere are a few other companies worth considering as our model shows that these too have the right combination of elements to beat on earnings this season:PVH Corp. PVH has an Earnings ESP of +4.84% and a Zacks Rank of 1, currently. You can see the complete list of today’s Zacks #1 Rank stocks here.Hanesbrands HBI has an Earnings ESP of +1.06% and a Zacks Rank of 2 at present.Five Below FIVE has an Earnings ESP of +3.90% and a Zacks Rank #3, presently. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. You know this company from its past glory days, but few would expect that it's poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks' Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hanesbrands Inc. (HBI): Free Stock Analysis Report PVH Corp. (PVH): Free Stock Analysis Report Gildan Activewear, Inc. (GIL): Free Stock Analysis Report Five Below, Inc. (FIVE): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksNov 3rd, 2021

Amedisys (AMED) Tops Q3 Earnings Estimates, Slashes "21 View

Amedisys (AMED) reports better-than-expected earnings for the third quarter on strong growth in the Home Health segment. Amedisys, Inc. AMED reported adjusted earnings per share (EPS) of $1.53 for third-quarter 2021, down 31.7% from the year-ago figure. The bottom line, however, beat the Zacks Consensus Estimate by 12.5%.The quarter’s adjustments include contingency accrual, certain COVID-related costs as well as benefits from CARES Act & State COVID-19 grants.GAAP EPS for the third quarter was $1.37, down 36.6% compared with the year-ago $2.16.Net service revenues grossed $553.5 million, up 1.7% year over year. The top line missed the Zacks Consensus Estimate by 2.7%.Segment in DetailWithin the Home Health division, net service revenues totaled $338.6 million in the quarter, reflecting a 3.9% rise year over year. Within this segment, Medicare revenues of $228.2 million improved 2.7% year over year. Non-Medicare revenues increased 6.4% to $110.4 million.Within the Hospice division, net service revenues were $197.5 million (down 1.1% year over year), including Medicare revenues of $187.8 million (down 0.6%) and non-Medicare revenues of $9.7 million (down 9.3%).Amedisys, Inc. Price, Consensus and EPS Surprise Amedisys, Inc. price-consensus-eps-surprise-chart | Amedisys, Inc. QuoteAt Personal Care, net service revenues totaled $15.9 million, reflecting a decline of 13.6% from the year-ago number. The High Acuity Care segment reported net service revenues of 1.5 million in the third quarter. The Corporate segment did not register any recognizable revenues in the third quarter.MarginsGross profit for the company declined 1.3% to $243.2 million in the quarter under review. Gross margin contracted 135 basis points (bps) to 43.9%.Expenses on salaries and benefits fell 3.1% to $119.4 million. Other expenses rose 11.8% to $55.2 million. Adjusted operating profit of $68.7 million reflected a 7.1% decline from the year-ago quarter. Adjusted operating margin contracted 118 bps to 12.4% from the prior-year level.Liquidity and Cash PositionAmedisys exited the third quarter of 2021 with cash and cash equivalents of $124.5 million compared with $91.7 million at the end of second-quarter 2021. The company's long-term obligations (excluding the current portion) were $434.8 million at the end of the third quarter compared with $179.4 million at the end of the last reported quarter.Cumulative net cash provided by operating activities at the end of the third quarter was $61.8 million compared with $83.1 million a year ago.2021 GuidanceAmedisys updated its outlook for 2021 for both core Amedisys and Contessa business, taking into account the rapidly-changing business environment posed by the COVID-19 pandemic, future regulations or government interventions, reduction in elective procedures, change in patient behavior and further decline in senior living occupancy  and other issues that can potentially impact the company’s core business.For 2021, the company anticipates net service revenues in the range of $2.200 billion to $2.205 billion, a drop from the earlier guidance of $2.230-$2.245. Adjusted earnings per share are projected in the range of $5.88-$5.93, a decline from the prior guidance of $6.37-$6.49.The Zacks Consensus Estimate for 2021 revenues is pegged at $2.25 billion. The Zacks Consensus Estimate for adjusted earnings per share is pegged at $6.09.Our TakeAmedisys ended the third quarter on a mixed note with better-than-expected earnings and a revenue miss. The Home Health division drove the top line in the reported quarter on growth in Medicare and Non-Medicare revenues. The recently-concluded Contessa Health buyout buoys optimism for the company.However, year-over-year decline in Hospice and Personal Care revenues is an added disadvantage. Further, the contraction of both margins does not bode well. The reduction in full-year guidance is concerning as well.Zacks Rank and Key PicksAmedisys currently carries a Zacks Rank #4 (Sell).Some better-ranked stocks in the broader medical space that have announced quarterly results are Thermo Fisher Scientific Inc. TMO, SARTORIUS SARTF and West Pharmaceutical Services, Inc. WST.Thermo Fisher, carrying a Zacks Rank #1 (Strong Buy), reported third-quarter 2021 adjusted EPS of $5.76, which beat the Zacks Consensus Estimate by 23.3%. Revenues of $9.33 billion outpaced the consensus mark by 12%. You can see the complete list of today’s Zacks #1 Rank stocks here.SARTORIUS reported third-quarter 2021 adjusted EPS of $2.55, surpassing the Zacks Consensus Estimate by 7.6%. Revenues of $1.06 billion surpassed the Zacks Consensus Estimate by 5.2%. It currently carries a Zacks Rank #2 (Buy).West Pharmaceutical reported third-quarter 2021 adjusted EPS of $2.06, which surpassed the Zacks Consensus Estimate by 13.2%. Revenues of $706.5 million outpaced the Zacks Consensus Estimate by 3.2%. It currently carries a Zacks Rank #2. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. You know this company from its past glory days, but few would expect that it's poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks' Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amedisys, Inc. (AMED): Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report SARTORIUS (SARTF): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksNov 3rd, 2021

CrowdStrike Holdings (CRWD) Outpaces Stock Market Gains: What You Should Know

CrowdStrike Holdings (CRWD) closed the most recent trading day at $270.65, moving +0.94% from the previous trading session. CrowdStrike Holdings (CRWD) closed at $270.65 in the latest trading session, marking a +0.94% move from the prior day. This move outpaced the S&P 500's daily gain of 0.65%.Prior to today's trading, shares of the cloud-based security company had gained 9.47% over the past month. This has outpaced the Computer and Technology sector's gain of 6% and the S&P 500's gain of 6.38% in that time.Investors will be hoping for strength from CRWD as it approaches its next earnings release. The company is expected to report EPS of $0.10, up 25% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $364.76 million, up 56.91% from the year-ago period.Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $0.47 per share and revenue of $1.41 billion. These totals would mark changes of +74.07% and +60.81%, respectively, from last year.Investors might also notice recent changes to analyst estimates for CRWD. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. CRWD is currently sporting a Zacks Rank of #3 (Hold).Looking at its valuation, CRWD is holding a Forward P/E ratio of 570.47. Its industry sports an average Forward P/E of 78.15, so we one might conclude that CRWD is trading at a premium comparatively.It is also worth noting that CRWD currently has a PEG ratio of 22.82. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Internet - Software industry currently had an average PEG ratio of 4.31 as of yesterday's close.The Internet - Software industry is part of the Computer and Technology sector. This industry currently has a Zacks Industry Rank of 165, which puts it in the bottom 36% of all 250+ industries.The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.To follow CRWD in the coming trading sessions, be sure to utilize Zacks.com. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. You know this company from its past glory days, but few would expect that it's poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks' Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CrowdStrike (CRWD): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Category: topSource: zacksNov 3rd, 2021

RCM Technologies, Inc. (RCMT) Outpaces Stock Market Gains: What You Should Know

RCM Technologies, Inc. (RCMT) closed at $6.42 in the latest trading session, marking a +1.42% move from the prior day. RCM Technologies, Inc. (RCMT) closed at $6.42 in the latest trading session, marking a +1.42% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.65%.Heading into today, shares of the company had gained 7.65% over the past month, outpacing the Business Services sector's gain of 2.57% and the S&P 500's gain of 6.38% in that time.RCMT will be looking to display strength as it nears its next earnings release. In that report, analysts expect RCMT to post earnings of -$0.02 per share. This would mark no growth from the year-ago period. Our most recent consensus estimate is calling for quarterly revenue of $42.22 million, up 33.77% from the year-ago period.Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $0.32 per share and revenue of $184.35 million. These totals would mark changes of +143.84% and +22.56%, respectively, from last year.Any recent changes to analyst estimates for RCMT should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. RCMT is holding a Zacks Rank of #3 (Hold) right now.Digging into valuation, RCMT currently has a Forward P/E ratio of 19.78. This represents a premium compared to its industry's average Forward P/E of 14.62.The Staffing Firms industry is part of the Business Services sector. This industry currently has a Zacks Industry Rank of 42, which puts it in the top 17% of all 250+ industries.The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.You can find more information on all of these metrics, and much more, on Zacks.com. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. You know this company from its past glory days, but few would expect that it's poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks' Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report RCM Technologies, Inc. (RCMT): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Category: topSource: zacksNov 3rd, 2021

Verisk"s (VRSK) Q3 Earnings & Revenues Surpass Estimates

Verisk's (VRSK) third-quarter 2021 earnings and revenues increase year over year. Verisk Analytics, Inc.VRSK reported solid third-quarter 2021 results, with earnings and revenues beating the Zacks Consensus Estimate.Adjusted earnings per share of $1.44 outpaced the consensus mark by 5.1% and grew 9.1% on a year-over-year basis. The upside was backed by organic growth within the business, lower interest expense, and lower average share count.Revenues of $759 million beat the consensus estimate by 0.6% and increased 8% year over year on a reported basis and 5.1% on an organic constant-currency (cc) basis.Over the past six months, shares of Verisk have improved 11% compared with 9.1% growth of the industry it belongs to and 11.2% increase of the Zacks S&P 500 composite.Image Source: Zacks Investment ResearchSegmental PerformanceInsurance segment revenues totaled $557.9 million, up 10.6% year over year on a reported basis and 7.4% on an organic cc basis.Within the segment, underwriting and rating revenues of $390.5 million rose 10.4% on a reported basis and 7% on an organic cc basis. The upside was primarily driven by an annual increase in prices derived from continued enhancements of the solutions’ contents within the industry-standard insurance programs, sale of expanded solutions to existing customers in commercial and personal lines, and contributions from catastrophe-modeling services and international software solutions.Claims revenues amounted to $167.4 million, improving 11.1% on a reported basis and 8.2% on an organic cc basis. The top line was positively impacted by repair cost estimating solutions revenues and claims analytics revenues. Energy and Specialized Markets segment revenues of $165.9 million increased 5% year over year on a reported basis and 2.5% on an organic cc basis. The uptick can be attributed to contributions from consulting, and environmental health and safety service revenues.Financial Services segment revenues of $35.2 million declined 12.7% year over year on a reported basis and 13.5% on an organic cc basis. The segment was weighed down by certain contract transitions, projects that did not reoccur and lower bankruptcy volumes. These declines more than offset the solid growth in spend informed analytics revenues.Operating ResultsAdjusted EBITDA of $378.8 million increased 3.5% on a reported basis and 2.1% on an organic cc basis. Adjusted EBITDA margin fell to 49.9% from 52.1% in the prior-year quarter.Verisk Analytics, Inc. Price, Consensus and EPS Surprise Verisk Analytics, Inc. price-consensus-eps-surprise-chart | Verisk Analytics, Inc. QuoteCash FlowVerisk generated $285.2 million of cash from operating activities and capex was $61.4 million. Free cash flow was $223.8 million.Share Repurchases & Dividend PayoutVerisk paid out a cash dividend of 29 cents per share on Sep 30. On Oct 27, the company's board of directors approved a quarterly cash dividend of 29 cents, payable on Dec 31, 2021, to holders of record as of Dec 15, 2021.During the reported quarter, the company repurchased almost 798,000 shares at an average price of $187.91 per share, for a total cost of $150 million. As of Sep 30, 2021, the company had $678.8 million available under its share repurchase authorization.Currently, Verisk carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Performance of Other Business Services CompaniesEquifax’s EFX third-quarter 2021 adjusted earnings of $1.85 per share beat the Zacks Consensus Estimate by 7.6% but declined on a year-over-year basis. Revenues of $1.22 billion outpaced the consensus estimate by 3.6% and improved 14.5% year over year on a reported basis and 14% on a local-currency basis.IQVIA’s IQV third-quarter 2021 adjusted earnings per share of $2.17 beat the consensus mark by 1.9% and improved 33.1% on a year-over-year basis. Total revenues of $3.39 billion outpaced the consensus estimate by 1% and increased 21.7% year over year on a reported basis and 21.1% on constant-currency basis.Omnicom’s OMC third-quarter 2021 adjusted earnings of $1.65 per share beat the consensus mark by 20.4% and increased 36.4% year over year. Total revenues of $3.4 billion surpassed the consensus estimate by 0.6% and increased 7.1% year over year. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. You know this company from its past glory days, but few would expect that it's poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks' Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Omnicom Group Inc. (OMC): Free Stock Analysis Report Equifax, Inc. (EFX): Free Stock Analysis Report Verisk Analytics, Inc. (VRSK): Free Stock Analysis Report IQVIA Holdings Inc. (IQV): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksNov 3rd, 2021

Bull Of The Day: Riot Blockchain (RIOT)

RIOT presents us with a unique opportunity to obtain bitcoin exposure at a sizable discount as its underlining profit driver takes flight It's time to gain exposure to the skyrocketing cryptocurrency market as a tidal wave of curious individual and institutional investors alike pour into this booming asset class.Riot Blockchain RIOT, now one of the world's largest public bitcoin miners following its recent acquisition of Whinestone US, is positioned to provide us with the rare and exciting opportunity to profit off the surging crypto market's already prolific rally. Bitcoin BTC rallied 125% in just three months (lows on July 20th and highs on October 20th) to notch a fresh all-time high just over $67,000 a coin, remaining buoyantly above $60K today. Roughly $1.5 trillion of value is being added to this legitimizing asset class as deep-pocketed institutional investors begin to deploy capital into this ambiguous market. The opportunity cost of not being a part of this rapidly appreciating asset class is just too great not to have some exposure.RIOT, which is closely tied to the performance of bitcoin, had initially overshot the crypto rally in the first month and a half of the year as momentum chasing traders such as the (self-proclaimed) "degenerates" on r/WallStreetBets (WSB) drove this leading miner's shares far above their intrinsic value. RIOT surged as much as 385% at the beginning of 2021, but its momentum-driven valuation bubble has since deflated. The stock is now trading over 65% below its highs to the value opportunity we see today.At the beginning of the year, euphoric purchases of short-term call options drove RIOT's moonshot price action, pushing it further out of institutional investors' scope of investible assets, and giving it the WSB seal of overvaluation. RIOT has fallen so far out of favor with the markets as of late that it has come down to a PEG (P/E to growth) of 0.67x (anything below one is considered undervalued), a discounted valuation multiple that can't be ignored amid this crypto explosion. With bitcoin's ripping rallying staying alive coupled with Riot Blockchain's continuous operational enhancements as its scales, analysts are getting increasingly bullish on RIOT, inflating EPS estimates across all timelines and propelling the stock into a Zacks Rank #1 (Strong Buy). All 5 of the covering sell-side analysts call RIOT a strong buy today, with an average price target of $52 a share, with some more bullish analysts giving it targets north of $80 (nearly 200% upside from here).The CatalystsUS cryptocurrency miners were given one the greatest gift they could have asked for when China and Xi's increasingly autocratic regime announced a reinforced ban on crypto mining earlier this year. 12 months ago, China controlled roughly 70% of the global bitcoin mining market, which is measured using hash rates. Hash rates are the speed at which cryptocurrencies are mined (attained through machine-based problem solving) and represent a measurement of computing power & efficiency (performance) of both individual & total market operations. The strict crypto mining banned in Asia's largest economy created a massive market hole, which US miners like Riot Blockchain quickly filled. The US is now the leading bitcoin miner by hash rate, controlling over 35% of this market, according to data from Cambridge Bitcoin Electricity Consumption Index (CBECI). Riot blockchain currently controls over 6% of the US's highly fragmented bitcoin mining market and is taking more share on a seemingly daily basis. This blockchain innovator's hash rate has more than quadrupled in the past year. Riot's savvy management team is projecting its hash rate will reach 4.4 EH/s (doubling its rate in September) before this year is up and reach 7.7 EH/s by the end of 2022.Its recent acquisition of Whinstone (the largest US crypto mining facility in the US) is the primary catalyst for its rapidly improving economies of scale forecast.First Bitcoin ETF Hits Exchanges Following SEC Chair Gary Gensler's landmark approval, the first bitcoin-linked exchange-traded fund (ETF) hit the NYSE last month. Bitcoin soared over $65k for the first time in history following this ETF's debut as institutional interest was further validated.ProShares Bitcoin Strategy ETF BITO became the first bitcoin futures-backed ETF to trade in the US, and its premiere performance was outstanding, with inflows of nearly $2 billion in its first two days of trading. This was a milestone for the crypto market as its futures ETF approval opens the door for institutional funds and wary investors to obtain exposure to this dubious (yet profitable) crypto market through trusted US government-approved exchanges. CME bitcoin futures (representing forward-looking derivative of the underlying asset) are the trusted crypto conduit the SEC is comfortable with exposing to the NYSE due to its regulatable nature – something that Defi (decentralized financial exchange) platforms, in which untraceable bitcoin trades, cannot claim. The one primary issue surrounding this conduit for bitcoin exposure is that futures contracts will need to be continuously rolled over to the front-month contract, which will cost money and cause decay to the ETF's value regarding bitcoin over time. You see this type of decay with virtually all commodity ETFs, similarly based on futures contracts. Nevertheless, this SEC approval is a massive step towards legitimizing the crypto space, gaining unprecedented market traction in recent years. Today marked a significant stride towards actual bitcoin-supported ETFs, but Gary Gensler and the rest of the apprehensive SEC will need some convincing before this occurs. Bitcoin bulls are on the hunt for $70k (trading within 1% of this level), which would mark a fresh all-time high for this currency of the future. Energy ConcernsThere has been growing attention surrounding the excessive use of energy required to power bitcoin mining facilities. Elon Musk is the most notable character voicing concerns about the use of fossil fuels to power digital asset mining operations, deciding to halt Tesla's TSLA bitcoin usage earlier this year because of it. Energy is also the most significant variable cost for blockchain-based enterprises like Riot, so it's central to assessing an investment in this unique space.Riot's primary operations are in Texas, ironically one of the cleanest and cheapest energy states (considering it's the oil capital of the US). The Electric Reliable Council of Texas (ERCOT) powers one of the few deregulated energy markets with a vast competitive push towards inexpensive and sustainable sources. Wind and solar make up nearly 30% of the ERCOT market's energy capacity, with relatively lower-carbon natural gas generating just over half.Free-market energy in Texas provides Riot with relatively inexpensive variable costs from increasingly clean sources.Final ThoughtsLike it or not, bitcoin is here to stay, and it's time to get some portfolio exposure, if you haven't already. RIOT presents us with a unique opportunity to obtain bitcoin exposure at a sizable discount as its underlining profit driver takes flightm, and its own controlling market share proliferates.RIOT has a significant competitive advantage in a market where scale means everything, with its recent acquisition of Whinstone leapfrogging its hash rate expansion. I would jump on this trade today before the window of opportunity for this rare high-growth value-play disappears. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tesla, Inc. (TSLA): Free Stock Analysis Report Riot Blockchain, Inc. (RIOT): Free Stock Analysis Report ProShares Bitcoin Strategy ETF (BITO): ETF Research Reports To read this article on Zacks.com click here......»»

Category: topSource: zacksNov 2nd, 2021

West Pharmaceutical (WST) Q3 Earnings & Revenues Beat Estimates

West Pharmaceutical's (WST) third-quarter earnings reflect segmental strong performance. West Pharmaceutical Services, Inc. WST reported third-quarter 2021 adjusted earnings per share (EPS) of $2.06, which beat the Zacks Consensus Estimate of $1.82 by 13.2%. The bottom line soared 79.1% year over year.GAAP EPS in the quarter was $2.31, up 112% from the prior-year quarter.Revenue DetailsThe company reported revenues of $706.5 million, which increased 28.9% from the prior-year quarter. The top line outpaced the Zacks Consensus Estimate by 3.2%.The company reported organic sales growth of 27.9%.Segment DetailsProprietary ProductsNet sales at the segment amounted to $577 million, reflecting year-over-year improvement of 36.9%. Organic sales growth came in at 35.7%. High-value products (components and devices) accounted for more than 70% of segment sales and delivered double-digit organic sales growth. Customer demand for FluroTec, Westar, NovaPure components and Daikyo Crystal Zenith containers led to the upside.West Pharmaceutical Services, Inc. Price, Consensus and EPS Surprise West Pharmaceutical Services, Inc. price-consensus-eps-surprise-chart | West Pharmaceutical Services, Inc. QuoteContract-Manufactured ProductsIn the reported quarter, net sales improved 2.4% year over year to $129.7 million. The segment delivered organic sales growth of 2.1%. Sales of healthcare-associated medical devices contributed to the improvement.MarginsGross profit in the reported quarter was $288.2 million, up 48.1% year over year. As a percentage of revenues, gross margin in the quarter was 40.8%, up 530 basis points (bps).Research and development expenses totaled $13.1 million, up 4.8% from the year-ago quarter. Selling, general and administrative expenses amounted to $91.9 million, up 20.6% on a year-over-year basis.Operating income was $181.4 million, up 82.9% year over year. As a percentage of revenues, operating margin in the quarter was 25.7%, up 760 bps.Financial PositionThe company exited the third quarter with cash and cash equivalents of $688 million, compared with $576.2 million in the previous quarter.Cumulative operating cash flow in the third quarter totaled $423.2 million, compared with $323.8 million in the prior-year period.Share Repurchase and Dividend AnnouncementDuring the first nine months of 2021, the company repurchased shares worth $131.7 million under its share repurchase program.With respect to dividend, the West Pharmaceutical’s board of directors approved a fourth-quarter 2021 dividend of 18 cents per share, an increase of 5.9% over 17 cents per share that was paid in each of the four trailing quarters. Interestingly, this marks the company’s 29th consecutive annual dividend hike.OutlookOn the back of the solid third-quarter 2021 performance, the company raised its full-year 2021 guidance.Net sales for full-year 2021 are projected between $2.80 billion and $2.81 billion (up from the prior range of $2.76-$2.79 billion). The Zacks Consensus Estimate for the same is currently pegged at $2.78 billion.Organic sales growth is estimated to be 28% (up from the prior range of 24-25%).Adjusted earnings per share for 2021 is anticipated in the band of $8.40 to $8.50 (up from the previous range of $8.05-$8.20 per share). Notably, this range includes an expected benefit of around 19 cents (compared to prior anticipated benefit of 27 cents) based on present foreign currency exchange rates.Wrapping UpWest Pharmaceutical exited third-quarter 2021 on a strong note, wherein both earnings and revenues beat the Zacks Consensus Estimate. The company witnessed strong performance across its segments. Expansion in both gross and operating margins in the reported quarter buoys optimism. Given the strength exhibited in the quarter under review, a raised 2021 outlook instills confidence.Per management, sustained momentum in organic sales growth in both its base business, and higher demand for its products related to COVID-19 vaccines drove the third-quarter results. The company delivered solid growth across all three of its Proprietary Products market units, driven by higher sales with respect to components in its HVP portfolio.However, increase in selling, general and administrative expenses remains a concern.Zacks RankWest Pharmaceutical currently carries a Zacks Rank #2 (Buy).Earnings of Other MedTech Majors at a GlanceSome other top-ranked stocks in the broader medical space that have already announced their quarterly results are Quest Diagnostics Incorporated DGX, Abbott Laboratories ABT, and HCA Healthcare, Inc. HCA, each carrying a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Quest Diagnostics reported third-quarter 2021 adjusted EPS of $3.96, which beat the Zacks Consensus Estimate by 33.8%. Third-quarter revenues of $2.77 billion outpaced the consensus mark by 12.6%.Abbott reported third-quarter 2021 adjusted EPS of $1.40, which surpassed the Zacks Consensus Estimate by 52.2%. Third-quarter revenues of $10.93 billion outpaced the Zacks Consensus Estimate by 15.3%.HCA Healthcare reported third-quarter 2021 adjusted EPS of $4.57, surpassing the Zacks Consensus Estimate by 11.5%. Revenues of $15.28 billion surpassed the Zacks Consensus Estimate by 4.7%. Bitcoin, Like the Internet Itself, Could Change Everything Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities. Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly. See 3 crypto-related stocks now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report HCA Healthcare, Inc. (HCA): Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksOct 28th, 2021